#daiichisankyo — Public Fediverse posts

To reduce its reliance on Enhertu ahead of the cancer treatment's patent expiry, Daiichi Sankyo is betting on a new wave of antibody-drug conjugates to expand its oncology business. https://www.japantimes.co.jp/business/2026/05/12/companies/daiichi-sankyo-new-cancer-drugs/?utm_medium=Social&utm_source=mastodon #business #companies #daiichisankyo #health #pharmaceuticals #medicine #patents

A Japanese panel of experts gave the green light for the health minister to approve the production and sale of Daiichi Sankyo's vaccine for measles, mumps and rubella. https://www.japantimes.co.jp/news/2026/03/03/japan/science-health/mmr-vaccine-ok-expert-panel/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #daiichisankyo #vaccinations #health #covid19 #medicine

Daiichi Sankyo said it would start over-the-counter sales of an emergency contraceptive pill on Feb. 2, marking the first time that such a pill will be sold without a prescription in Japan. https://www.japantimes.co.jp/news/2025/12/18/japan/science-health/japan-otc-emergency-contraception/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #pharmaceutical #health #pregnancy #birthcontrol #daiichisankyo

AstraZeneca and Daiichi Sankyo’s drug Datroway has significantly improved survival and delayed the progression of breast cancer in patients with a particularly hard to treat form of the disease, AstraZeneca has said. https://www.japantimes.co.jp/business/2025/10/07/companies/astrazeneca-breast-cancer/?utm_medium=Social&utm_source=mastodon #business #companies #astrazeneca #daiichisankyo #health #cancer #medicine #pharmaceuticals

AstraZeneca and Daiichi Sankyo’s Datroway breast cancer treatment, which the companies expect will eventually become a blockbuster, was recommended for approval in the European Union. https://www.japantimes.co.jp/business/2025/01/31/astrazeneca-daiichi-eu-approval/?utm_medium=Social&utm_source=mastodon #business #daiichisankyo #astrazeneca #cancer #medicine #pharmaceuticals #eu

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a milestone in the company’s efforts to turn it into a widely used blockbuster. https://www.japantimes.co.jp/business/2025/01/20/companies/daiichi-sankyo-breast-cancer-treatment/?utm_medium=Social&utm_source=mastodon #business #companies #daiichisankyo #pharmaceuticals #breastcancer #us #astrazeneca

AstraZeneca and Daiichi Sankyo won U.S. approval for a novel breast cancer treatment, a milestone in the companies’ efforts to turn the medicine into a widely used blockbuster. https://www.japantimes.co.jp/business/2025/01/18/cancer-drug-astrazeneca-daiichi/?utm_medium=Social&utm_source=mastodon #business #daiichisankyo #astrazeneca #medicine #cancer #pharmaceuticals

Tokyo District Court on Wednesday sentenced a former employee of drugmaker Daiichi Sankyo to 16 years in prison for the murder of his wife by methanol poisoning in 2022. https://www.japantimes.co.jp/news/2024/10/31/japan/crime-legal/methanol-murder-16-years-prison/ #japan #crimelegal #drugs #japanesecourts #daiichisankyo

Prosecutors have called for an 18-year prison sentence for Keisuke Yoshida, a 42-year-old former employee of pharmaceutical giant Daiichi Sankyo, who is on trial for the methanol poisoning death of his wife. https://www.japantimes.co.jp/news/2024/10/11/japan/crime-legal/methanol-poisoning-trial/ #japan #crimelegal #japanesecourts #tokyo #daiichisankyo

Drugmaker Daiichi Sankyo is working to boost production of its newer-generation cancer therapies that target diseased cells, across Japan, Europe and the United States. https://www.japantimes.co.jp/business/2024/10/11/companies/daiichi-sankyo-cancer-drug/ #business #companies #daiichisankyo #cancer #drugs #astrazeneca

Cancer drug powerhouse Daiichi Sankyo has its sights on the next generation of targeted oncology drugs, and this time it might not need a partner to get it over the line. https://www.japantimes.co.jp/news/2024/09/17/japan/science-health/daiichi-sankyo-cancer-drugs/ #japan #sciencehealth #daiichisankyo #pharmaceutical #medicine #cancer #drugs

A former employee of pharmaceutical company Daiichi Sankyo who is accused of poisoning his wife to death with methanol in 2022 denied the charge on Monday. https://www.japantimes.co.jp/news/2024/09/02/japan/crime-legal/court-methanol-poisoning/ #japan #crimelegal #japanesecourt #tokyo #otaward #daiichisankyo

The COVID-19 pandemic highlighted many weaknesses in Japan’s health care system. It's now time to fix them with a global perspective, says health minister Keizo Takemi. https://www.japantimes.co.jp/news/2024/08/14/japan/science-health/health-minister-keizo-takemi-interview/ #japan #sciencehealth #keizotakemi #dementia #aging #pandemic #covid19 #medicine #pharmaceuticals #daiichisankyo #covid19injapan #covid19vaccines

Health Minister Keizo Takemi sat down with the Japan Times to talk about his vision of digitalizing Japan’s health care system, as well as sharing the country’s medical know-how with other Asian nations. https://www.japantimes.co.jp/news/2024/08/14/japan/science-health/health-minister-keizo-takemi-interview-124346/ #japan #sciencehealth #keizotakemi #dementia #aging #pandemic #covid19 #medicine #pharmaceuticals #daiichisankyo #covid19injapan #covid19vaccines

Japan’s health ministry approved the first domestically developed COVID-19 vaccine that works against the currently circulating XBB.1.5 sublineage of the omicron variant. https://www.japantimes.co.jp/news/2023/11/28/japan/science-health/daiichi-sankyo-covid-vaccine/?utm_content=bufferc45df&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #sciencehealth #pharmaceuticals #daiichisankyo #covid19injapan #covid19vaccines #medicine #covid19

U.S. drugmaker Merck will pay Daiichi Sankyo $5.5 billion (about ¥824.7 billion) to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the Japanese firm. https://www.japantimes.co.jp/business/2023/10/20/daiichi-sankyo-merck-cancer-deal/?utm_content=bufferfef3c&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #business #daiichisankyo #merck #health #medicine #cancer

A Japanese health ministry panel has endorsed a COVID-19 vaccine developed by pharmaceutical company Daiichi Sankyo, a first for a domestically developed shot. https://www.japantimes.co.jp/news/2023/08/01/japan/science-health/japan-panel-endorses-first-domestically-developed-covid-vaccine/?utm_content=buffer0d11e&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #japan #sciencehealth #pharmaceuticals #daiichisankyo #covid19injapan #covid19vaccines #medicine #shionogi #covid19

Daiichi Sankyo is expanding its sales and development staff overseas, aiming to boost production capacity so that it can handle its cancer drugs business entirely on its own. https://www.japantimes.co.jp/news/2023/06/07/business/corporate-business/daiichi-sankyo-interview/?utm_content=buffer3a51c&utm_medium=social&utm_source=mastodon&utm_campaign=bffmstdn #news #corporate #cancer #astrazeneca #daiichisankyo #medicine #enhertu